Joining the wave of healthcare IPOs this year, amid Fed rate cut expectations, Guardian Pharmacy Services, Inc. is preparing to go public.
Guardian Pharmacy seeks to raise up to $108 mil in US IPO
Categories
biopharma
Everything you need to know about Zenas BioPharma’s IPO
Zenas BioPharma, Inc. is among the latest healthcare companies to jump on the IPO bandwagon, filing its prospectus even as the market
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company focused on transforming biomedical inventions into cutting-edge therapies. The company develops novel therapies
Ocean Biomedical announces loan commitment of up to $10 million from largest stockholder
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers to develop and commercialize their discoveries,
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business
Ocean Biomedical (OCEA) announces new findings in relation to treatment options for Hermansky-Pudlak Syndrome
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) announced its commitment to developing viable treatment options for Hermansky-Pudlak Syndrome (HPS) on Thursday. The
Infographic: Ocean Biomedical Inc. (OCEA) quarter ended June 30, 2022
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here are the company’s numbers for
AbbVie sees near-term slowdown; looks prepared to tackle patent expiration
AbbVie, Inc. (NYSE: ABBV) has delivered yet another quarter of strong top-line and earnings performance but issued cautious guidance for fiscal 2023
Infographic: Highlights of Gilead Sciences (GILD) Q4 2022 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when
Avid Bioservices Inc (CDMO) Q2 2023 Earnings Call Transcript
Avid Bioservices Inc (NASDAQ:CDMO) Q2 2023 Earnings Call dated Dec. 07, 2022. Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President & Chief Executive
Is Merck & Co. (MRK) a good investment after Q1 earnings?
Merck & Co., Inc. (NYSE: MRK) is recovering from the virus-induced slowdown supported by stable demand across its product line globally, a
ANI Pharmaceuticals, Inc. (ANIP) Q4 2021 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) Q4 2021 earnings call dated Mar. 15, 2022 Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- President and Chief
AbbVie (ABBV) Earnings: Key financials and quarterly highlights
AbbVie (NYSE: ABBV) today reported its fourth-quarter financial results for the period ended December 31, 2021. Net revenues increased 7.4% to $14.8
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing
Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook
Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also
AbbVie (ABBV) stock research summary | Q3 2021
The AlphaStreet research report provides actionable data and insights into AbbVie’s fundamentals, the industry, and competition. The report is meant as a
Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ: CARA) Q3 2021 earnings call dated Nov. 08, 2021 Corporate Participants: Will Gramig -- Senior Analyst Derek Chalmers -- Chief Executive Officer,
Earnings: AbbVie (ABBV) Q3 profit rises, beats estimates on higher revenues
Biopharmaceutical company AbbVie Inc. (NYSE: ABBV) on Friday said its third-quarter revenues and net profit increased from last year. The results also
Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell. The revenue increased by 13%
IPO news: Cingulate is making its market debut this week, here’s what to know
The biopharmaceuticals market was valued at approx. $325.17 billion in 2020 and it is expected to grow at a CAGR of 7.3%
IPO News: Here are a few things to note when Dice Therapeutics goes public
Many pharma companies are lining up to go public and this week will see Dice Therapeutics join the group. The California-based firm,